---
title: 'Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab
  for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome'
date: '2023-11-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37962590/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231114170859&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: TBIR should be considered as differential diagnosis in
  patients with NMOSD presenting with disturbed glucose metabolism, irrespective of
  the presence of SLE. More real-world data are needed on the risk/benefit ratio of
  ECU treatment in patients who have co-existing autoimmune comorbidities that may
  compromise immune function. Strategies to mitigate the risk of serious infection
  in patients treated with ECU are ...'
disable_comments: true
---
CONCLUSIONS: TBIR should be considered as differential diagnosis in patients with NMOSD presenting with disturbed glucose metabolism, irrespective of the presence of SLE. More real-world data are needed on the risk/benefit ratio of ECU treatment in patients who have co-existing autoimmune comorbidities that may compromise immune function. Strategies to mitigate the risk of serious infection in patients treated with ECU are ...